Accelerate Diagnostics

Accelerate Diagnostics Cash Conversion

Delisted

The Cash Conversion Rate (OCF/Net Income) of Accelerate Diagnostics (AXDX) as of Nov 10, 2026 is 48.34 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 65.23 % — a change of -25.89% (lower).

Cash Conversion

48.34 %

YoY

-25.89%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Accelerate Diagnostics is 2024 48.34 % . Cash Conversion Rate (OCF/Net Income) of Accelerate Diagnostics was 2023 65.23 % . It decreases by -25.89% lower compared to the previous year.

The Accelerate Diagnostics Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2017
88.65 USD
Jan 1, 2018
76.71 USD
Jan 1, 2019
76.86 USD
Jan 1, 2020
64.44 USD
Jan 1, 2021
60.90 USD
Jan 1, 2022
77.97 USD
Jan 1, 2023
65.23 USD
Jan 1, 2024
48.34 USD
The Accelerate Diagnostics Cash Conversion history
YEARCash ConversionYoY
48.34 %-25.89%
65.23 %-16.34%
77.97 %+28.03%
60.90 %-5.48%
64.44 %-16.16%
76.86 %+0.19%
76.71 %-13.47%
88.65 %+10.17%
80.47 %+4.23%
77.20 %+27.13%
60.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections. Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accelerate Diagnostics stock

Cash Conversion Rate (OCF/Net Income) of Accelerate Diagnostics is 48.34 % in 2024.

Cash Conversion Rate (OCF/Net Income) of Accelerate Diagnostics changed from 65.23 % to 48.34 %, representing a -25.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Accelerate Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Accelerate Diagnostics

All Key Metrics — Accelerate Diagnostics